A share price of Spyre Therapeutics Inc [SYRE] is currently trading at $29.2, up 8.27%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The SYRE shares have gain 21.16% over the last week, with a monthly amount glided 18.84%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Spyre Therapeutics Inc [NASDAQ: SYRE] stock has seen the most recent analyst activity on September 26, 2025, when Deutsche Bank initiated its Buy rating and assigned the stock a price target of $43. Previously, Leerink Partners started tracking the stock with Outperform rating on April 08, 2025, and set its price target to $45. On March 18, 2025, Wolfe Research initiated with an Outperform rating and assigned a price target of $27 on the stock. Wedbush started tracking the stock assigning an Outperform rating and suggested a price target of $45 on September 04, 2024. Evercore ISI initiated its recommendation with an Outperform. Robert W. Baird started tracking with an Outperform rating for this stock on May 02, 2024, and assigned it a price target of $50. In a note dated March 01, 2024, Wells Fargo upgraded an Overweight rating on this stock and boosted its target price from $12 to $35.
Spyre Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $10.91 and $29.06. Currently, Wall Street analysts expect the stock to reach $43 within the next 12 months. Spyre Therapeutics Inc [NASDAQ: SYRE] shares were valued at $29.2 at the most recent close of the market. An investor can expect a potential return of 47.26% based on the average SYRE price forecast.
Analyzing the SYRE fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.3, Equity is -0.31 and Total Capital is -0.47.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 27.40 points at the first support level, and at 25.59 for the second support level. However, for the 1st resistance point, the stock is sitting at 30.25, and for the 2nd resistance point, it is at 31.30.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Spyre Therapeutics Inc [NASDAQ:SYRE] is 10.90. Also, the Quick Ratio is 10.90, while the Cash Ratio stands at 1.4.
Transactions by insiders
Recent insider trading involved Turtle Cameron, Chief Executive Officer, that happened on Nov 03 ’25 when 45000.0 shares were sold. Director, CAMERON TURTLE completed a deal on Nov 03 ’25 to buy 90000.0 shares. Meanwhile, Chief Financial Officer Burrows Scott L sold 18428.0 shares on Sep 02 ’25.
